Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs 5,539

Quick answer

Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Pipeline programs

Page 97 of 116

  1. ION537

    IONIS PHARMACEUTICALS INC

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  2. IOR-BMS-IST-002

    The George Institute

    Non-small cell lung cancer (NSCLC)

    phase 1 other active

    1 trial

  3. IOV-2001

    Iovance Biotherapeutics B.V.

    Chronic Lymphocytic Leukemia

    phase 1 mab completed

    1 trial

  4. IPH4502-101

    Lacuna Pharma Pty Ltd

    Advanced Solid Tumors

    phase 1 other active

    1 trial

  5. IRX4204

    IO Biotech

    Lung Cancer, Nonsmall Cell

    phase 1 small molecule terminated

    1 trial

  6. IRX5183

    IO Biotech

    Acute Myeloid Leukemia (AML)

    phase 1 small molecule terminated

    1 trial

  7. IVAC MUTANOME, RBL001/RBL002

    Atrium Therapeutics

    Melanoma

    phase 1 mab completed

    1 trial

  8. IXAZOMIB

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  9. Image Guided Dynamic Dosimetry

    United Therapeutics Europe Ltd

    Locally Confined Adenocarcinoma of the Prostate

    phase 1 other completed

    1 trial

  10. Imatinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumor Cancer

    phase 1 small molecule active

    1 trial

  11. Imatinib/Acetaminophen

    Novartis Pharmaceuticals

    Chronic Myeloid Leukemia (CML)

    phase 1 small molecule completed

    1 trial

  12. Improving Peptide Receptor Radionuclide Therapy with PARP inhibitors

    Disc Medicine

    locally advanced or metastatic, well-differentiated gastro-enteropancreatic neuroendocrine tumors.

    phase 1 other active

    1 trial

  13. Infigratinib

    BridgeBio Oncology Therapeutics

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  14. Infigratinib

    BridgeBio Oncology Therapeutics

    Bladder Transitional Cell Carcinoma

    phase 1 small molecule terminated

    1 trial

  15. Intraperitoneal infusion of FAST CEA-targeted CAR-T

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    2 trials

  16. Intravenous Artesunate

    United Therapeutics Europe Ltd

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  17. Intravenous Vitamin C

    CNS Pharmaceuticals

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  18. Investigator-Selected Standard PD-1/PD-L1 Inhibitor-Based Therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Solid Tumors

    phase 1 small molecule active

    1 trial

  19. Invivo CAR-T

    Chongqing Precision Biotech Co., Ltd

    B-Acute Lymphoblastic Leukemia

    phase 1 mab active

    1 trial

  20. Iopofosine I 131

    Cellectar Biosciences

    Breast Cancer

    phase 1 small molecule active

    1 trial

  21. Ipatasertib

    Hoffmann-La Roche

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  22. Ipilimumab

    Regeneron UK Limited

    Stage III Prostate Cancer

    phase 1 mab terminated

    1 trial

  23. Ipilimumab

    VACCINEX, INC.

    Pathologic Stage IIIB Cutaneous Melanoma AJCC v8

    phase 1 mab active

    1 trial

  24. Irinotecan Accord 20 mg/ml concentraat voor oplossing voor infusie

    Disc Medicine

    Gastric cancer

    phase 1 small molecule active

    1 trial

  25. Irinotecan liposome II combination therapy regimen

    Chongqing Claruvis Pharmaceutical Co.,

    Non-Muscle Invasive Bladder Urothelial Carcinoma

    phase 1 small molecule active

    1 trial

  26. Itraconazole

    United Therapeutics Europe Ltd

    Non-small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  27. Ivosidenib

    Agios Netherlands B.V.

    IDH1 Mutation Myeloid Neoplasms

    phase 1 small molecule completed

    1 trial

  28. Ixazomib

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  29. Ixazomib

    Takeda

    Precursor Cell Lymphoblastic Leukemia-lymphoma

    phase 1 small molecule terminated

    1 trial

  30. J5J-OX-JZZA

    Eli Lilly Co.

    KRAS G12D-mutant solid tumors.

    phase 1 other active

    1 trial

  31. J5Q-OX-JRDA

    Eli Lilly Co.

    Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS.

    phase 1 other active

    1 trial

  32. JANX007

    Janux Therapeutics

    Prostate Cancer

    phase 1 mab active

    1 trial

  33. JANX008

    Janux Therapeutics

    Non-Small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  34. JANX014

    Janux Therapeutics

    Prostate Cancer

    phase 1 mab active

    1 trial

  35. JNJ-56021927

    Janssen Cilag International NV

    Prostatic Neoplasms, Castration-Resistant

    phase 1 small molecule completed

    1 trial

  36. JR8603

    JiaRay Group

    Solid Tumors

    phase 1 small molecule active

    1 trial

  37. JSB462

    Novartis Pharmaceuticals

    Metastatic Prostate Cancer (mCRPC)

    phase 1 small molecule active

    1 trial

  38. JWCAR029 (CD19-targeted Chimeric Antigen Receptor Cells)

    Shanghai University of Traditional Chinese Medicine

    Diffuse Large B Cell Lymphoma

    phase 1 mab completed

    1 trial

  39. JZP341

    Jazz Pharmaceuticals Ireland Limited

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  40. JZP815

    Jazz Pharmaceuticals Ireland Limited

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  41. JZP898

    Jazz Pharmaceuticals Ireland Limited

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  42. Jiu-wei-zhen-xiao Granule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatocellular Carcinoma

    phase 1 small molecule completed

    1 trial

  43. KCP-330

    Karyopharm Therapeutics Inc

    Sarcoma

    phase 1 small molecule completed

    1 trial

  44. KFA115

    Novartis Pharmaceuticals

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule active

    1 trial

  45. KISIMA-02 vaccine-based immunotherapy for patients with pancreatic cancer

    Boehringer Ingelheim

    G12D/G12V Pancreatic Ductal Adenocarcinoma

    phase 1 other active

    1 trial

  46. KK-LC-1 TCR-T cells

    Iovance Biotherapeutics B.V.

    Gastric Cancer

    phase 1 mab active

    1 trial

  47. KN-8701/KIN2787CI101

    Pierre Fabre Medicament

    Participants with BRAF and/or NRAS mutation positive tumors

    phase 1 other active

    1 trial

  48. KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

    Kura Oncology

    Pancreatic Ductal Adeno Carcinoma, Colorectal Cancer, Non- Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma

    phase 1 other active

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.